Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer

被引:14
|
作者
Wagner, Jamie [1 ]
Boughey, Judy C. [1 ]
Garrett, Betsy [1 ]
Babiera, Gildy [1 ]
Kuerer, Henry [1 ]
Meric-Bernstam, Funda [1 ]
Singletary, Eva [1 ]
Hunt, Kelly K. [1 ]
Middleton, Lavinia P. [1 ]
Bedrosian, Isabelle [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
来源
AMERICAN JOURNAL OF SURGERY | 2009年 / 198卷 / 03期
关键词
Breast; Lobular cancer; Margins; Neoadjuvant chemotherapy; Local recurrence; BREAST-CONSERVATION THERAPY; CARCINOMA IN-SITU; LOCAL RECURRENCE; CONSERVING THERAPY; SURGERY; OUTCOMES; RISK;
D O I
10.1016/j.amjsurg.2009.01.006
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Optimal surgical management of patients with invasive lobular carcinoma (ILC) who undergo neoadjuvant chemotherapy (NAC) is unknown. We evaluated optimal margin distance and local recurrence (LR) rates for these patients. METHODS: Ninety-three (30%) of 311 patients with ILC received NAC. We examined margin status, residual disease after re-excision, and clinical outcomes. RESULTS: Margin positivity rates after the final operative procedure were similar between the NAC and surgery-first group (P > .05). The proportion of patients, stratified by margin status, who were taken back for re-excision was not different between the 2 groups, and, similarly, there were no differences in frequency of residual disease (all P > .05) At a median follow-up of 3.1 years, 1 patient in the NAC group and 2 in the surgery-first group developed LR (P = 1.0). CONCLUSIONS: Patients with ILC who have undergone NAC and have margins >1 mm have a low probability of residual disease and LR. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:387 / 391
页数:5
相关论文
共 50 条
  • [1] Predictive factors associated with invasive lobular breast cancer after neoadjuvant chemotherapy
    Julian, T. B.
    Anderson, S.
    Fourchotte, V.
    Zieger, S.
    Mamounas, E.
    Bear, H.
    Costantino, J.
    Wolmark, N.
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 17 - 17
  • [2] Neoadjuvant Chemotherapy and Completion Mastectomies in Invasive Lobular Breast Cancer
    Ramalingam, Kirithiga
    Mukhtar, Rita
    Mujir, Firdows
    Clelland, Elle
    Rothschild, Harriet
    Record, Helena
    Kaur, Mandeep
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S192 - S192
  • [3] Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer
    Esther H. Lips
    Rita A. Mukhtar
    Christina Yau
    Jorma J. de Ronde
    Chad Livasy
    Lisa A. Carey
    Claudette E. Loo
    Marie-Jeanne T. F. D. Vrancken-Peeters
    Gabe S. Sonke
    Donald A. Berry
    Laura J. van‘t Veer
    Laura J. Esserman
    Jelle Wesseling
    Sjoerd Rodenhuis
    E. Shelley Hwang
    Breast Cancer Research and Treatment, 2012, 136 : 35 - 43
  • [4] Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer
    Lips, Esther H.
    Mukhtar, Rita A.
    Yau, Christina
    de Ronde, Jorma J.
    Livasy, Chad
    Carey, Lisa A.
    Loo, Claudette E.
    Vrancken-Peeters, Marie-Jeanne T. F. D.
    Sonke, Gabe S.
    Berry, Donald A.
    van't Veer, Laura J.
    Esserman, Laura J.
    Wesseling, Jelle
    Rodenhuis, Sjoerd
    Hwang, E. Shelley
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (01) : 35 - 43
  • [5] Response Rates of Invasive Lobular Cancer in Patients Undergoing Neoadjuvant Endocrine or Chemotherapy
    Jakub, James W.
    Zhang, Wenexia
    Solanki, Malvika
    Yonkus, Jennifer
    Boughey, Judy C.
    Harmsen, Scott
    Giridhar, Karthik, V
    AMERICAN SURGEON, 2023, 89 (02) : 230 - 237
  • [6] Response rates of patients with invasive lobular cancer undergoing neoadjuvant endocrine or chemotherapy
    Giridhar, Karthik
    Zhang, Wenxia
    Solanki, Malvika
    Boughey, Judy
    Yonkus, Jennifer
    Harmsen, William
    Jakub, James
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 1) : 195 - 196
  • [7] Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
    Gottipati, S.
    Earl, H. M.
    Yau, C.
    Cameron, D. A.
    Abraham, J.
    Hayward, L.
    Reyal, F.
    Osdoit, M.
    Sonke, G. S.
    Wesseling, J.
    Boughey, J.
    Goetz, M. P.
    DeMichele, A.
    Pusztai, L.
    Sharma, P.
    Martin Jimenez, M.
    Lopez-Tarruella Cobo, S.
    Del Monte-Millan, M.
    Symmans, F.
    Mukhtar, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S325 - S326
  • [8] Clinical relevance of neoadjuvant chemotherapy in invasive lobular carcinoma of the breast
    Vrancken, Peeters M-JTFD
    Linn, S. C.
    Loo, C. E.
    Peterse, H. L.
    Rutgers, EJTh
    Rodenhuis, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S231 - S232
  • [9] Characterizing Response to Neoadjuvant Chemotherapy in Invasive Lobular Breast Carcinoma
    Riba, Luis A.
    Russell, Teresa
    Alapati, Amulya
    Davis, Roger B.
    James, Ted A.
    JOURNAL OF SURGICAL RESEARCH, 2019, 233 : 436 - 443
  • [10] Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer
    W. Truin
    G. Vugts
    R. M. H. Roumen
    A. J. G. Maaskant-Braat
    G. A. P. Nieuwenhuijzen
    M. van der Heiden-van der Loo
    V. C. G. Tjan-Heijnen
    A. C. Voogd
    Annals of Surgical Oncology, 2016, 23 : 51 - 57